Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.373 USD | +1.47% | +1.21% | -92.81% |
May. 07 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
May. 07 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 1.57M | Sales 2025 * | 672K | Capitalization | 22.41M |
---|---|---|---|---|---|
Net income 2024 * | -82M | Net income 2025 * | -75M | EV / Sales 2024 * | 14.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 33.3 x |
P/E ratio 2024 * |
-0.3
x | P/E ratio 2025 * |
-0.4
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.92% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | +3.32% | ||
1 week | -4.89% | ||
Current month | -92.88% | ||
1 month | -93.19% | ||
3 months | -92.69% | ||
6 months | -87.41% | ||
Current year | -92.98% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 0.377 | +2.56% | 4 922 621 |
24-05-16 | 0.3676 | +3.32% | 2,188,369 |
24-05-15 | 0.3558 | -4.35% | 2,386,473 |
24-05-14 | 0.372 | +2.59% | 3,774,479 |
24-05-13 | 0.3626 | -2.66% | 2,592,227 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.98% | 22.41M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.28% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- LYRA Stock